These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 2565962)
1. In-vivo effects of (E)-2-(3',4'-dimethoxyphenyl)-3-fluoroallylamine (MDL 72145) on amine oxidase activities in the rat. Selective inhibition of semicarbazide-sensitive amine oxidase in vascular and brown adipose tissues. Elliott J; Callingham BA; Barrand MA J Pharm Pharmacol; 1989 Jan; 41(1):37-41. PubMed ID: 2565962 [TBL] [Abstract][Full Text] [Related]
2. An allylamine derivative (MDL 72145) with potent irreversible inhibitory actions on rat aorta semicarbazide-sensitive amine oxidase. Lyles GA; Fitzpatrick CM J Pharm Pharmacol; 1985 May; 37(5):329-35. PubMed ID: 2862241 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species. Yu PH; Zuo DM Biochem Pharmacol; 1992 Jan; 43(2):307-12. PubMed ID: 1739419 [TBL] [Abstract][Full Text] [Related]
4. Semicarbazide-sensitive amine oxidase (SSAO) of the rat aorta. Interactions with some naturally occurring amines and their structural analogues. Elliott J; Callingham BA; Sharman DF Biochem Pharmacol; 1989 May; 38(9):1507-15. PubMed ID: 2719723 [TBL] [Abstract][Full Text] [Related]
5. Further studies on the ex-vivo effects of procarbazine and monomethylhydrazine on rat semicarbazide-sensitive amine oxidase and monoamine oxidase activities. Holt A; Callingham BA J Pharm Pharmacol; 1995 Oct; 47(10):837-45. PubMed ID: 8583353 [TBL] [Abstract][Full Text] [Related]
7. Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Carpéné C; Abello V; Iffiú-Soltész Z; Mercier N; Fève B; Valet P Pharmacol Res; 2008 Jun; 57(6):426-34. PubMed ID: 18539478 [TBL] [Abstract][Full Text] [Related]
8. Amine oxidase activities in brown adipose tissue of the rat: identification of semicarbazide-sensitive (clorgyline-resistant) activity at the fat cell membrane. Barrand MA; Fox SA J Pharm Pharmacol; 1984 Oct; 36(10):652-8. PubMed ID: 6150080 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of rat aorta semicarbazide-sensitive amine oxidase by 2-phenyl-3-haloallylamines and related compounds. Lyles GA; Marshall CM; McDonald IA; Bey P; Palfreyman MG Biochem Pharmacol; 1987 Sep; 36(17):2847-53. PubMed ID: 3632710 [TBL] [Abstract][Full Text] [Related]
10. MDL 72145, an enzyme-activated irreversible inhibitor with selectivity for monoamine oxidase type B. Zreika M; McDonald IA; Bey P; Palfreyman MG J Neurochem; 1984 Aug; 43(2):448-54. PubMed ID: 6736960 [TBL] [Abstract][Full Text] [Related]
11. Reduction of fat deposition by combined inhibition of monoamine oxidases and semicarbazide-sensitive amine oxidases in obese Zucker rats. Carpéné C; Iffiú-Soltesz Z; Bour S; Prévot D; Valet P Pharmacol Res; 2007 Dec; 56(6):522-30. PubMed ID: 17977742 [TBL] [Abstract][Full Text] [Related]
12. Glucose handling in streptozotocin-induced diabetic rats is improved by tyramine but not by the amine oxidase inhibitor semicarbazide. Visentin V; Bour S; Boucher J; Prévot D; Valet P; Ordener C; Parini A; Carpéné C Eur J Pharmacol; 2005 Oct; 522(1-3):139-46. PubMed ID: 16202994 [TBL] [Abstract][Full Text] [Related]
13. Studies of monoamine oxidase and semicarbazide-sensitive amine oxidase. I. Inhibition by a selective monoamine oxidase-B inhibitor, MD 780236. Kinemuchi H; Morikawa F; Ueda T; Arai Y Jpn J Pharmacol; 1986 Jun; 41(2):183-9. PubMed ID: 3747265 [TBL] [Abstract][Full Text] [Related]
14. Comparative ex vivo inhibitory effects of (E)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine (MDL 72145) on amine oxidase activities in the rat. Lyles GA; Marshall CM; Flucker CJ Biochem Pharmacol; 1989 Sep; 38(17):2937-40. PubMed ID: 2775316 [No Abstract] [Full Text] [Related]
15. Design and early clinical evaluation of selective inhibitors of monoamine oxidase. Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532 [TBL] [Abstract][Full Text] [Related]
16. Studies on the behaviour of semicarbazide-sensitive amine oxidase in Sprague-Dawley rats treated with the monoamine oxidase inhibitor tranylcypromine. Fitzgerald DH; Tipton KF; Lyles GA J Neural Transm Suppl; 1998; 52():259-64. PubMed ID: 9564625 [TBL] [Abstract][Full Text] [Related]
17. Semicarbazide-sensitive amine oxidase and monoamine oxidase in rat brain microvessels, meninges, retina and eye sclera. Zuo DM; Yu PH Brain Res Bull; 1994; 33(3):307-11. PubMed ID: 8293314 [TBL] [Abstract][Full Text] [Related]
19. Characterization of human serum and umbilical artery semicarbazide-sensitive amine oxidase (SSAO). Species heterogeneity and stereoisomeric specificity. Yu PH; Zuo DM; Davis BA Biochem Pharmacol; 1994 Mar; 47(6):1055-9. PubMed ID: 8147904 [TBL] [Abstract][Full Text] [Related]
20. Deamination of aliphatic amines by type B monoamine oxidase and semicarbazide-sensitive amine oxidase; pharmacological implications. Yu PH; Davis BA; Boulton AA; Zuo DM J Neural Transm Suppl; 1994; 41():397-406. PubMed ID: 7931256 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]